Sheldon Sloan

CMO Sheldon Sloan sells 8,333 shares of SYRE for $624,975 under pre-arranged 10b5-1 plan; retains 313,334 options

Sheldon Sloan, Chief Medical Officer, sold 8,333 shares at $75.00 on 2026-06-03 totaling $624,975.00, pursuant to a 10b5-1 trading plan adopted on 2025-06-20 (scheduled, not discretionary). The sale represents his non-derivative holdings; he retains 313,334 shares in stock options post-transaction. The company is unprofitable with net income of $-69,005,000.00 for the most recent full fiscal year and $0.00 revenue in the latest quarter. Across his same-ticker history at SYRE, Sloan's prior five sales on 2026-05-01 showed mixed near-term outcomes (30-day range: -0.3% to +5.7%; 90-day range: -6.2% to -0.5%), with the 90-day returns consistently negative. At current price of $73.52, the stock is -6.7% from the 52-week high of $78.80 but +6.4% over 30 days and +81.1% over 90 days.

CMO Sloan Sheldon sells entire 78,333-share position for $5.6M at $71.50 avg on May 1, 2026.

Chief Medical Officer Sloan Sheldon executed 7 separate sales totaling 78,333 shares for $5,600,701.16 on 2026-05-01, liquidating his entire shareholding at prices ranging from $69.53 to $75.37. The transaction occurred while SYRE trades at $69.42 (current price), just 6.8% below its 52-week high of $74.45, but the company remains unprofitable with a net loss of $-11,183,000.00 over its most recent full fiscal year and zero revenue in the latest quarter. The complete elimination of the CMO's holdings at near-peak valuations warrants scrutiny given the company's underlying financial distress, particularly as the 30-day and 90-day momentum metrics (+42.0% and +117.1% respectively) may reflect speculative price movements rather than fundamental improvement.